European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry

June 19, 2007 updated by: Jagiellonian University

European Registry on Patients With ST-Elevation MI Transferred for Mechanical Reperfusion (PCI)With a Special Focus on Upstream Use of Abciximab

EUROTRANSFER Registry is a prospective, international, web-based European Registry on Patients with ST-Elevation MI Transferred for Mechanical Reperfusion (PCI) with a Special Focus on Upstream Use of Abciximab.

This registry is designed to collect data on approximately 1800 patients during a 12 month enrollment period in up to 20 interventional cardiology centres with hospital transfer networks from all over Europe.

Analysis of this registry should allow to monitor transfer timelines of patients arriving to the cath-lab from the regional hospital with or without upstream start of abciximab and scheduled for mechanical reperfusion (PCI) as well as to monitor regional differences across Europe in regard to the impact that time of various stages of the treatment chain may have on clinical outcomes.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment

1800

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Finland
      • Helsinki, Finland
        • Helsinki University Central Hospital
  • Germany
      • Villingen, Germany
        • Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
  • Italy
      • Arezzo, Italy
        • San Donato Hospital
      • Mantova, Italy
        • Ospedale Carlo Poma
      • Massa, Italy
        • Ospedale G.Pasquinucci
      • Reggio Emilia, Italy
        • Santa Maria Nuova Hospital Reggio Emilia
      • Treviso, Italy
        • Ospedale S.Maria di Ca Foncello
  • Poland
      • Krakow, Poland, 31-501
        • Cardiac Catheterization Laboratories Jagiellonian University Medical College, University Hospital
      • Krakow, Poland
        • Department of Interventional Cardiology, John Paul II Hospital
      • Przemysl, Poland
        • Szpital Wojewódzki w Przemyślu
      • Tarnow, Poland
        • Szpital im. Szczeklika Tarnow
  • Slovenia
      • Ljubljana, Slovenia
        • University Medical Center Ljubljana
  • Spain
      • Coruna, Spain
        • Hospital Juan Canalejo
      • Santiago de Compostela, Spain
        • Hospital Clinico Universitario
  • Sweden
      • Linköping, Sweden
        • Linkoping University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

PATIENTS:

  • All consecutive STEMI patients >=18years arriving to the Cath Lab hospital (invasive facility center) from transfer.

    • Transfer with respect to this registry is defined as patients that reach the Cath Lab hospital:

      1. transferred from a surrounding regional community hospitals that the Cath Lab hospital has an established referral pattern with or

      2. after being picked-up by an ambulance which is equipped/staffed to provide specific medical therapy (like prehospital thrombolysis or upstream abciximab). Usually these have a physician or specifically trained nurse on board.

        CENTRES:

    • Provide 24 hour/7 days on duty PCI service.
    • Has an established regional hospital referral network with >=8 patients/month arriving from transfer (as defined above).
    • A rate of >=10% of these transfer patients who receive upstream abciximab before or during transfer to the Cath Lab hospital. Start of abciximab in the ER or CCU of the Cath Lab hospital will not be considered as upstream start of abciximab.

Exclusion Criteria:

  • Patients who arrive to the Cath Lab from other pathways than those specified above (a. and b.), e.g. those who come by ambulances that do not provide specific medical therapy or arrive directly to the ER of the Cath Lab hospital by own feet/car will not be included in this registry.
  • Patients from controlled clinical trials shall be included as long as their actual treatment is fully known. Thus, participants from randomized trials with blinded treatment cannot be included in this registry.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Defined Population
  • Time Perspectives: Other

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jagiellonian University

Collaborators

Foundation for Medical Research in Krakow, Poland

Investigators

  • Principal Investigator: Dariusz Dudek, Assoc. Prof., Cardiac Catheterization Laboratories, Jagiellonian University Medical College
  • Study Chair: Zbigniew Siudak, MD, Cardiac Catheterization Laboratories, Jagiellonian University Medical College
  • Study Director: Lukasz Partyka, MD, PhD, KCRI

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2005

Primary Completion

December 7, 2022

Study Completion

February 1, 2007

Study Registration Dates

First Submitted

September 19, 2006

First Submitted That Met QC Criteria

September 19, 2006

First Posted (Estimate)

September 20, 2006

Study Record Updates

Last Update Posted (Estimate)

June 20, 2007

Last Update Submitted That Met QC Criteria

June 19, 2007

Last Verified

June 1, 2007

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • H4S-PL-O067

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Coronary Syndrome

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe